Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Topical ABL01 Treatment of Onychomycosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03141840
Recruitment Status : Completed
First Posted : May 5, 2017
Last Update Posted : February 20, 2019
Sponsor:
Information provided by (Responsible Party):
Abbell AB

Brief Summary:
This clinical trial seeks to investigate if an experimental medical device, ABL01, can be used to treat onychomycosis. In a 1-year trial the effectiveness of ABL01 will be tested against placebo in 70 study subjects with onychomycosis of the big toe nail. The endpoint of the trial is clinical improvement and cure at the 6 and 12 month time-point.

Condition or disease Intervention/treatment Phase
Onychomycosis of Toenail Device: ABL01 Device: Placebo Not Applicable

Detailed Description:

The purpose of this clinical trial is to determine the safety and effectiveness of the medical device ABL01. The intended use of ABL01 is to reduce and treat onychomycosis, fungal nail infection. ABL01 is a solution intended to be topically administered weekly to infected nails. The trial is designed as a double blinded randomized placebo controlled clinical trial. The trial involves 70 study subjects, half of which will receive ABL01 and the other half placebo. The inclusion criteria for study subjects are adult men and women that present with distal lateral subungual onychomycosis (DSU) on the big toe nails. Furthermore, the extent of DSU should not involve more than half of the area of the nail.

The study subjects will themselves apply the study solution weekly to the treated nail. The trial will run for 6 months with a possible extension to maximum 12 months. There will be a total of 4 study visits at baseline, 3, 6 and 12 months to follow up the progress of the trial. The primary objective of the trial is to determine if ABL01 treatment are able to reduce and treat onychomycosis. Secondary objectives are to collect safety data, determine if the ABL01 are perceived as easy to use and assess long term effects of the treatment. The endpoint of the trial is reduction in clinical signs or complete cure of onychomycosis at the 6- or 12-month time-point.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double blind randomized controlled trail comparing ABL01 and placebo.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Study subjects are randomly assigned to treatment or placebo groups by a predetermined algoritm using sealed envelopes.
Primary Purpose: Treatment
Official Title: Clinical Trial of Safety and Efficacy of Topical ABL01 Treatment of Onychomycosis
Actual Study Start Date : August 14, 2017
Actual Primary Completion Date : February 8, 2019
Actual Study Completion Date : February 8, 2019

Arm Intervention/treatment
Experimental: Experimental
Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
Device: ABL01
Experimental medical device

Placebo Comparator: Control
Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
Device: Placebo
ABL01 lacking active component




Primary Outcome Measures :
  1. Number of study subjects with a reduction in infected nail area at 6 months. [ Time Frame: 6 months ]
    Clinical improvement of the condition is assessed by analyzing changes in infected nail area (in relation to total nail area) due to ABL01 or placebo treatment. Clinical improvement is considered to be a 40% reduction in infected area at the 6 month time period.


Secondary Outcome Measures :
  1. Questionnaire regarding subjects opinion of the treatment, nail improvement. [ Time Frame: 12 months ]
    Subjects score (1-5) the perceived improvement of their nail condition.

  2. Questionnaire regarding subjects opinion of the treatment, ease of use. [ Time Frame: 12 months ]
    Subjects score (1-5) the perceived ease of using ABL01.

  3. Number of study subjects with treatment-related adverse events [ Time Frame: 12 months ]
    Subject reported safety data in combination with reported adverse events and adverse device effects related to the topical administration of ABL01.

  4. Number of study subjects with a reduction in infected area of the nail [ Time Frame: 12 months ]
    Clinical improvement of the condition is assessed by analyzing changes in infected nail area (in relation to total nail area) due to ABL01 or placebo treatment. Clinical improvement is considered to be a 80% reduction in infected area at the 12 month time period.

  5. Number of study subjects with clinical cure [ Time Frame: 12 months ]
    Clinical cure is established with a negative test for dermatophytes as assessed by DNA-analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provision of written informed consent
  • Men and women above age 18 weighing over 40 kg
  • Present with distal lateral subungual onychomycosis of any of the big toe nails
  • The onychomycosis should involve less than 50 % of the nail bed and may not have reached the cuticle

Exclusion Criteria:

  • Unable to come for study visits
  • Known allergy to any of the components in ABL01
  • Not willing to participate in the trial or not able to understand the content of the trial
  • Present with proximal subungual onychomycosis or superficial onychomycosis.
  • Present with distal lateral subungual onychomycosis of other nails than the big toe.
  • More than 50 % of the nailbed affected by onychomycosis or the cuticles infected
  • Known conditions (like psoriasis) that cause abnormal nail appearance
  • Nail damage caused by trauma, pressure or other mechanical reasons
  • Currently on immunosuppressive therapy
  • Showing signs of poor peripheral blood circulation
  • Used another topical antifungal treatment within 1 month of screening
  • Used a systemic antifungal treatment within 3 months of screening
  • Participated in any other clinical onychomycosis trial in the previous 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03141840


Locations
Layout table for location information
Sweden
Fotcompaniet Stockholm
Stockholm, Sweden, 113 52
Sponsors and Collaborators
Abbell AB
Investigators
Layout table for investigator information
Principal Investigator: Irini Mouratidou-Kontorinis Fotcompaniet Stockholm

Layout table for additonal information
Responsible Party: Abbell AB
ClinicalTrials.gov Identifier: NCT03141840     History of Changes
Other Study ID Numbers: AB001
First Posted: May 5, 2017    Key Record Dates
Last Update Posted: February 20, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Onychomycosis
Tinea
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Nail Diseases
Skin Diseases